Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record.

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

Open access
Danese, Silvio, Fiorino, Gionata, Raine, Tim, Ferrante, Marc, Kemp, Karen, Kierkus, Jaroslaw, Lakatos, Peter L., Mantzaris, Gerassimos, van der Woude, Janneke, Panes, Julian, Peyrin-Biroulet, Laurent·2017·Journal of Crohn's and Colitis

Abstract

Biosimilars of infliximab were first approved by the European Medicine Agency in 2013,1,2 based on pre-clinical studies on biosimilarity and on clinical data coming from two randomised controlled trials conducted in rheumatoid arthritis [RA] and ankylosing spondylitis [AS].3,4 Initially the European Crohn’s Colitis Organisation [ECCO] raised some caution on the use of biosimilars.5 This cautious approach was also supported by several national inflammatory bowel disease [IBD] societies5–12 [Table 1]. An insufficient understanding of the characteristics and use of biosimilars became evident in a web survey among ECCO members in the same period.13 ... Since biosimilars were introduced in the EU market in early 2015, more data from IBD patients14–19 have supported the biosimilarity of biosimilar infliximab CT-P13 and the reference product, with no significant differences in terms of efficacy or safety, in either naïve or switched patients in cohort studies. Importantly, a study showed clear cross-reactivity between the infliximab originator and CT-P13.20 Recently, a large nationwide Norwegian randomised controlled trial [NOR-SWITCH] on patients with immune-mediated diseases [Crohn’s disease; ulcerative colitis; psoriasis; psoriatic arthritis; RA and AS] found no differences in terms of clinical response, maintenance of remission, or adverse events in patients receiving CT-P13 compared with those receiving originator infliximab.21 Consideration of these findings22 together with a better understanding of the process of biosimilar development and regulatory approval, have contributed to a change in the perception of IBD experts, who now prescribe biosimilars with significantly more confidence.23

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ecco-jcc/jjw198

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 248

Metadata

Authors
Danese, S., Fiorino, G., Raine, T., Ferrante, M., Kemp, K., Kierkus, J., Lakatos, P. L., Mantzaris, G., van der Woude, J., Panes, J., & Peyrin-Biroulet, L.
Venue
Journal of Crohn's and Colitis
Published
2016-12-07
Volume
11
Issue
1
Pages
26-34
ISSN
  • 1873-9946 (ISSN-L)
  • 1876-4479
OpenAlex
W2560455300
Cited by
248
References
0
FWCI
17.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjw198
The paper
Danese, S., Fiorino, G., Raine, T., Ferrante, M., Kemp, K., Kierkus, J., Lakatos, P. L., Mantzaris, G., van der Woude, J., Panes, J., & Peyrin-Biroulet, L. (2017). ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjw198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.